Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: The CERTAIN double-blind, randomised, placebo-controlled trial

Smolen, JS, Emery, P, Ferraccioli, GF et al. (7 more authors) (2015) Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: The CERTAIN double-blind, randomised, placebo-controlled trial. Annals of the Rheumatic Diseases, 74 (5). pp. 843-850. ISSN 0003-4967

Abstract

Metadata

Authors/Creators:
  • Smolen, JS
  • Emery, P
  • Ferraccioli, GF
  • Samborski, W
  • Berenbaum, F
  • Davies, OR
  • Koetse, W
  • Purcaru, O
  • Bennett, B
  • Burkhardt, H
Copyright, Publisher and Additional Information: © 2015, BMJ Publishing Group Ltd and the European League Against Rheumatism. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
Dates:
  • Accepted: 14 December 2013
  • Published (online): 15 January 2014
  • Published: May 2015
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Clinical Musculoskeletal Medicine (LIRMM) (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 23 Jun 2016 10:17
Last Modified: 23 Jun 2016 10:21
Published Version: http://dx.doi.org/10.1136/annrheumdis-2013-204632
Status: Published
Publisher: BMJ Publishing Group
Identification Number: https://doi.org/10.1136/annrheumdis-2013-204632

Export

Statistics